Strategic Analysis of World Psychiatric Therapeutics Markets
Strategic Analysis of World Psychiatric Therapeutics Markets
RELEASE DATE
28-Sep-2004
28-Sep-2004
REGION
Global
Global
Research Code: A847-01-00-00-00
SKU: HC00981-GL-MR_04857
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
HC00981-GL-MR_04857
Description
This research service evaluates the emerging psychiatric therapeutics markets, specifically anticonvulsants, antidepressants, and antipsychotics. Factors affecting market growth, existing market trends, pipeline trends, challenges, strategic product profiles, revenue analysis, and awards are presented for each therapeutic area.
Table of Contents
Overview
- Introduction
- Disclaimer
- Certification
- Research Scope and Methodology
- Study Objectives
- Market Segmentation by Geographical Region
- Market Segmentation by Indications
Total Market Overview
- Market Dynamics Overview
- Research and Development Overview
- Executive Quote
Anticonvulsant Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Demand Analysis
- Industry Challenges
- Market Drivers
- Market Restraints
- Revenue Potential
- Product Pipeline Analysis
- Product Analysis: Pregabalin
- Product Analysis: Rufinamide
Antidepressants Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Demand Analysis
- Percent of Treated vs. Untreated Patients
- Industry Challenges
- Market Drivers
- Market Restraints
- Product Pipeline Analysis
- Product Analysis: Cymbalta
- Product Analysis: DVS-233 SR
- Product Analysis: Gepirone ER
- Product Analysis: SR 58611
Antipsychotic Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Industry Challenges
- Market Drivers
- Market Restraints
- Product Pipeline Analysis
- CEO Quote
- Product Analysis: Bifeprunox
Competitive Landscape
- Company Analysis
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Eli Lilly
- Johnson and Johnson
- Wyeth
- Novartis
- Forest Laboratories
- Organon
- Anticipating the Future
Frost & Sullivan Awards
- Introduction
- Competitive Strategy Leadership Award
- Product Innovation Award - Antipsychotic Markets
- Product Innovation Award - Antidepressant Markets
- Growth Strategy Leadership Award
Decision Support Databases
- Psychiatrics
- Neurologists
- Alzheimer's Patients
- Population 65 and Above
- Physicians
Frost & Sullivan
- Healthcare Team
- Our Capabilities
- Key Advantages
- Our Consulting Clients
- Growth Consulting
- Growth Consulting Process
- Growth Consulting Deliverables
- Growth Partnership Service
- Growth Partnership Service Platform
Popular Topics
This research service evaluates the emerging psychiatric therapeutics markets, specifically anticonvulsants, antidepressants, and antipsychotics. Factors affecting market growth, existing market trends, pipeline trends, challenges, strategic product profiles, revenue analysis, and awards are presented for each therapeutic area.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | A847-01-00-00-00 |
Is Prebook | No |